Polypills and 3D Printing: The Next Frontier of Personalized Medicine

Read More @ https://www.techdogs.com/t...

In 2026, the pharmaceutical industry is defined by Bio-Digital Integration, where Generative AI is used for de novo drug design and decentralized manufacturing allows for 3D-printed personalized medicine at the point of care. The rise of Digital Therapeutics (DTx) and blockchain-verified supply chains ensures that treatments are both hyper-personalized and securely tracked from lab to patient.